Additionally, our research suggests that antagonising the BD1 domain of Brd4 may not be as innocuous as previously believed, as its delayed side effects, such as accelerated ageing or age‐related neurodegenerative diseases, may manifest over time. Here, BRD4 is linked to neurodegenerative disease.